This commentary explores legal, ethical, and practical considerations for pharmacists and prescribers working together to address uncertainty in drug prescribing.
AMA J Ethics. 2021;23(6):E471-479. doi:
10.1001/amajethics.2021.471.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
This third era of opioids ruining thousands of US lives follows a first era of iatrogenic addiction stemming from the Harrison Act of 1914, and a second was marked by changes in pain treatment attitudes between 1950 and 1970.
AMA J Ethics. 2020;22(8):E729-734. doi:
10.1001/amajethics.2020.729.
Before a deadly heroin overdose at 27, Jean-Michel Basquiat finished an electrically vibrant skull, prompting questions today about arts donations generated by opioid profits.
AMA J Ethics. 2020;22(8):E735-738. doi:
10.1001/amajethics.2020.735.